Cbd Life Science Stock Price, News & Analysis

CBD Life Sciences (OTC:CBDL) announced on November 18, 2025 the launch of its Tremendous Anti-Inflammatory Soothe Gel at two Red Hots Spa locations in New York: Garden City Hotel (Garden City) and Roslyn.

The topical formula lists menthol, camphor, and capsaicin as active ingredients and is described as engineered for immediate cooling relief and deep tissue penetration. CBDL positions the rollout as an East Coast retail expansion that expands The CBD Vault's physical footprint and wholesale catalog while targeting the luxury spa wellness market.

CBD Life Sciences (OTC Pink: CBDL) announced a repeat bulk order from Bronx dispensary Smoking Scholars on November 12, 2025, supplying three premium hemp flower strains from its branded unit The CBD Vault: Hawaii Haze (hybrid), Jet Fuel (sativa) and Purple Gas (indica).

The release highlights a 1405.46% revenue increase since February 2024 and positions CBDL to expand distribution in New York’s cannabis market, which the release cites as projected to reach $7.2B by 2030. The company frames the order as evidence of recurring wholesale demand and growing retail placement momentum.

CBD Life Sciences (OTC: CBDL) launched two hemp-free, vegan gummies on October 28, 2025: Energy Boost Gummies (100 mg) and Diet & Weight-Loss Gummies (100 mg). Both formulas use plant-based ingredients—Energy: green tea extract, caffeine, BCAA, L-Arginine; Diet: maca, caffeine, yohimbe, guarana, bitter orange.

The company cites a growing gummy supplements market projected to exceed $50 billion by 2030, positioning these SKUs to expand distribution into fitness, nutrition, pharmacy, and e-commerce channels and to diversify revenue beyond CBD products.

CBD Life Sciences (OTC PINK:CBDL) announced the launch of a Mushroom-Infused Dubai Chocolate Bar through its subsidiary CBD Vault on October 21, 2025. The premium bar blends pistachio-filled Dubai-style chocolate with Cordyceps and Reishi extracts, positioning the company at the intersection of luxury confectionery and functional wellness.

The release cites the Dubai chocolate market > $1.5 billion with a 6.8% annual growth rate and a projected $35 billion global functional mushroom market by 2030 (CAGR 10.8%). CBDL says it will add the product to its Mushroom Madness line and pursue international and domestic distribution, expecting recurring revenue in Q4 2025 and through 2026.

CBD Life Sciences (OTC:CBDL) announced a major retail expansion after a large order from Smoking Scholars dispensary in the Bronx on October 14, 2025. CBDL's top-selling beverages — 16oz 50mg CBD Lemonade, 16oz 25mg CBD Raspberry Lemonade, 16oz 25mg CBD Lavender Lemonade, and CBD-infused water — will appear on Smoking Scholars' shelves, supporting the company’s East Coast retail push.

The company cites strong consumer demand, NECANN conference leads, and a growing regional pipeline across New Jersey and Pennsylvania, with management projecting recurring bulk orders and potential six-figure monthly sales as additional dispensaries onboard.

CBD Life Sciences (OTC:CBDL) has secured a strategic partnership with Smoking Scholars, a premier Bronx dispensary, marking a significant expansion into the New York cannabis market. The agreement includes an initial order of various CBD products including pain relief cream, massage oil, gummies, tea, and mushroom face cream.

The partnership emerged following CBDL's successful showcase at the NECANN New Jersey Conference and is expected to generate hundreds of thousands in revenue within 12 months. This move positions CBDL strategically in the New York market, where dispensary sales are projected to reach $4.4 billion by 2027. The company is actively pursuing additional partnerships across the Northeast region.

CBD Life Sciences (OTC:CBDL) has signed a Letter of Intent (LOI) with a licensed New Jersey dispensary, marking a strategic entry into the East Coast cannabis market. The partnership establishes a unique dual-channel distribution model where CBD Vault's products will be featured in the New Jersey dispensary while the dispensary's products will be sold in CBDL's retail locations.

The company expects this partnership to generate seven-figure annual revenues and serve as a springboard for expansion in the East Coast corridor. The New Jersey cannabis market alone is projected to exceed $2 billion annually by 2026, while the broader U.S. CBD and cannabis sector is forecasted to reach $33 billion by 2030.

CBD Life Sciences Inc. (OTC:CBDL) reports significant momentum following its participation at NECANN New Jersey 2025, one of the largest cannabis trade shows in the country. The company has entered into advanced negotiations with five major dispensaries across Pennsylvania & New Jersey, potentially accessing thousands of retail customers.

CBDL is also expanding its beverage portfolio, with CBD Seltzer and CBD Lemonade Drink planned for distribution in sports stadiums. The U.S. marijuana dispensary market is projected to reach $31.8 billion annually by 2025, with CBD-infused beverages showing a CAGR exceeding 20%. The company's dual strategy focuses on dispensary expansion and mass-market beverage distribution in sports venues.

CBD Life Sciences (OTC:CBDL) reports that President Trump's administration is actively considering rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act. This potential regulatory shift could transform the $30+ billion cannabis market by eliminating IRS Section 280E restrictions and opening doors for institutional investment.

The rescheduling would enable cannabis companies to deduct ordinary business expenses, improve net margins, and facilitate access to banking services. With nearly 70% of Americans supporting legalization, CBDL is positioning itself through retail expansion, including recent approval for sales on Walmart Marketplace, to capitalize on the anticipated industry growth following regulatory reform.